Axsome Therapeutics Inc AXS-07 MOMENTUM Results Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to Axsome Therapeutics Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Mr. Mark Jacobson, Senior Vice President of Operations at Axsome Therapeutics. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining us on today's conference call to discuss the positive top line results from the MOMENTUM Phase III trial of AXS-07 in migraine patients with a history of inadequate response to prior acute treatment. A press release announcing that AXS-07 achieved the co-primary endpoints in the trial crossed the wire a short time ago and is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |